SCHEMBL3019505

SCHEMBL3019505

COc1cc(OC)cc(-c2csc(N3CCC(S(=O)(=O)c4cc(C)c(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.45
HSD17B10 Q99714 3/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 8/20 0.41
LMNA P02545 6/20 0.41
MAPK1 P28482 6/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
NPC1 O15118 3/20 0.41
HPGD P15428 1/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
GAA P10253 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 2/20 0.39
POLB P06746 1/20 0.39
MMP1 P03956 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008835 0.92 SMN1; SMN2 (0.55) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL15671701 0.91 MAPT (0.57) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3008704 0.89 SMN1; SMN2 (0.45) MAPTRAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL3011210 0.89 MAPK1 (0.53) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL3019957 0.89 SMN1; SMN2 (0.42) MAPTRAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL3010191 0.88 MAPT (0.54) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL3016467 0.87 MAPT (0.47) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL3015770 0.87 RAB9A (0.46) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL3012415 0.87 MAPK1 (0.44) MAPTHSD17B10USP2RECQLRAB9A
SCHEMBL3017858 0.86 SMN1; SMN2 (0.54) MAPTHSD17B10USP2RECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.